All In Biotech

Drug Trial Radar · NCT02881086

Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients

Last checked: Nov 20, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,023 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,023

Actual

Start

Aug 2016

Primary completion

Dec 2024

Study completion Dec 2024

Sponsor

Lead sponsor
Goethe UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 26, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase IV study with the primary goal to optimize therapy of adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma (LBL) by dose and time intensive, pediatric based chemotherapy, risk adapted stem cell transplantation (SCT) and minimal residual disease (MRD) based individualised and intensified therapy. Study will further evaluate the role of asparaginase intensification, the extended use of rituximab and the use of nelarabine as consolidation therapy in T-ALL in a phase III-part of the study. Furthermore two randomisations will focus on the role of central nervous system (CNS) irradiation in combination with intrathecal therapy versus intrathecal therapy only in B-precursor ALL/LBL and the role of SCT in high-risk patients with molecular complete remission. Finally a new, dose reduced induction therapy in combination with Imatinib will be evaluated in Ph/BCR-ABL positive ALL.

Conditions

  • Acute Lymphoblastic Leukemia
  • Lymphoblastic Lymphoma

Interventions

  • RituximabDrug

  • NelarabineDrug

  • PEG-AsparaginaseDrug

  • Cranial irradiationProcedure

  • ImatinibDrug

  • IdarubicinDrug

  • DexamethasoneDrug

  • CyclophosphamideDrug

  • FludarabineDrug

  • VincristineDrug

  • MercaptopurineDrug

  • VP16Drug

  • Daunorubicin (DNR)Drug

  • MethotrexateDrug

  • Stem cell transplantationProcedure

  • CytarabineDrug

  • VindesineDrug

  • AdriamycinDrug

  • PrednisoloneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event free survivalTime frame: 3.5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Frankfurt (Main)

    Frankfurt am Main, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.